Hepatitis C and renal transplantation in era of new antiviral agents

Table 3 Recommended regimens for kidney transplant patients

Recommended	Duration	Rating
Recommended regimens listed by evidence level and alphabetically for treatment-naive and experienced kidney transplant patients with genotype 1 or 4 infection, with or without compensated cirrhosis
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)	12 wk	I, A1
		IIa, C2
Daily fixed dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 wk	I, A
Recommended and alternative regimens for treatment-naïve and experienced kidney transplant patients with genotype 2, 3, 4, 5 or 6 infection, with or without compensated cirrhosis
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)	12 wk	I, A3
		IIa, C4
Alternative
Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) plus low initial dose of ribavirin (600 mg; increased as tolerated)	12 wk	II, A

¹Patients without cirrhosis;

²Patients with compensated cirrhosis;

³Genotypes 2, 3 and 6;

⁴Genotype 5.